Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of N6022 to Evaluate Safety and Pharmacokinetics in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation (SNO1)

NCT01746784 is registered in ClinicalTrials.gov with Nivalis Therapeutics, Inc. as lead sponsor.

NCT NCT01746784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01746784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of N6022 to Evaluate Safety and Pharmacokinetics in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation (SNO1)
Lead sponsor
Nivalis Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2014
Completion date
May 31, 2014
Enrollment
66 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis